Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 33
Current Topics in Behavioral Neurosciences ; 61:v-vii, 2023.
Article in English | EMBASE | ID: covidwho-2318979
Topics in Antiviral Medicine ; 31(2):94-95, 2023.
Article in English | EMBASE | ID: covidwho-2318189
Journal of Investigative Medicine ; 71(1):53, 2023.
Article in English | EMBASE | ID: covidwho-2316453
Circ Res ; 132(10): 1405-1424, 2023 May 12.
Article in English | MEDLINE | ID: covidwho-2318962


SARS-CoV-2, the virus underlying COVID-19, has now been recognized to cause multiorgan disease with a systemic effect on the host. To effectively combat SARS-CoV-2 and the subsequent development of COVID-19, it is critical to detect, monitor, and model viral pathogenesis. In this review, we discuss recent advancements in microfluidics, organ-on-a-chip, and human stem cell-derived models to study SARS-CoV-2 infection in the physiological organ microenvironment, together with their limitations. Microfluidic-based detection methods have greatly enhanced the rapidity, accessibility, and sensitivity of viral detection from patient samples. Engineered organ-on-a-chip models that recapitulate in vivo physiology have been developed for many organ systems to study viral pathology. Human stem cell-derived models have been utilized not only to model viral tropism and pathogenesis in a physiologically relevant context but also to screen for effective therapeutic compounds. The combination of all these platforms, along with future advancements, may aid to identify potential targets and develop novel strategies to counteract COVID-19 pathogenesis.

COVID-19 , Humans , SARS-CoV-2 , Microfluidics , Microphysiological Systems
European Respiratory Journal Conference: European Respiratory Society International Congress, ERS ; 60(Supplement 66), 2022.
Article in English | EMBASE | ID: covidwho-2247908
Hum Cell ; 36(3): 894-907, 2023 May.
Article in English | MEDLINE | ID: covidwho-2230739


Blood transfusions are now an essential part of modern medicine. Transfusable red blood cells (RBCs) are employed in various therapeutic strategies; however, the processes of blood donation, collection, and administration still involve many limitations. Notably, a lack of donors, the risk of transfusion-transmitted disease, and recent pandemics such as COVID-19 have prompted us to search for alternative therapeutics to replace this resource. Originally, RBC production was attempted via the ex vivo differentiation of stem cells. However, a more approachable and effective cell source is now required for broader applications. As a viable alternative, pluripotent stem cells have been actively used in recent research. In this review, we discuss the basic concepts related to erythropoiesis, as well as early research using hematopoietic stem cells ex vivo, and discuss the current trend of in vitro erythropoiesis using human-induced pluripotent stem cells.

COVID-19 , Pluripotent Stem Cells , Humans , Erythropoiesis , Erythrocytes , Hematopoietic Stem Cells , Cell Differentiation/genetics
Acta Physiologica ; 237(Supplement 727):8, 2023.
Article in English | EMBASE | ID: covidwho-2223248
Altex ; 37(4):U2, 2020.
Article in English | EMBASE | ID: covidwho-2170062
Phenotyping of Human iPSC-derived Neurons: Patient-Driven Research ; : 173-200, 2022.
Article in English | Scopus | ID: covidwho-2149084
Research and Practice in Thrombosis and Haemostasis Conference ; 6(Supplement 1), 2022.
Article in English | EMBASE | ID: covidwho-2128277
Journal of the American Society of Nephrology ; 33:410, 2022.
Article in English | EMBASE | ID: covidwho-2125389
Therapeutic Delivery ; 13(5):275-281, 2022.
Article in English | EMBASE | ID: covidwho-2066908
Neuromethods ; 189:173-190, 2023.
Article in English | EMBASE | ID: covidwho-2059680
Pharmaceuticals (Basel) ; 15(6)2022 Jun 20.
Article in English | MEDLINE | ID: covidwho-1974874


Since December 2019, the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected ~435 million people and caused ~6 million related deaths as of March 2022. To combat COVID-19, there have been many attempts to repurpose FDA-approved drugs or revive old drugs. However, many of the current treatment options have been known to cause adverse drug reactions. We employed a population-based drug screening platform using 13 human leukocyte antigen (HLA) homozygous human induced pluripotent cell (iPSC) lines to assess the cardiotoxicity and neurotoxicity of the first line of anti-COVID-19 drugs. We also infected iPSC-derived cells to understand the viral infection of cardiomyocytes and neurons. We found that iPSC-derived cardiomyocytes express the ACE2 receptor which correlated with a higher infection of the SARS-CoV-2 virus (r = 0.86). However, we were unable to detect ACE2 expression in neurons which correlated with a low infection rate. We then assessed the toxicity of anti-COVID-19 drugs and identified two cardiotoxic compounds (remdesivir and arbidol) and four neurotoxic compounds (arbidol, remdesivir, hydroxychloroquine, and chloroquine). These data show that this platform can quickly and easily be employed to further our understanding of cell-specific infection and identify drug toxicity of potential treatment options helping clinicians better decide on treatment options.

Gastroenterology ; 162(7):S-314, 2022.
Article in English | EMBASE | ID: covidwho-1967297
Cardiovascular Research ; 118:i90, 2022.
Article in English | EMBASE | ID: covidwho-1956562